MEDICATION TREATMENT: Ursodeoxycholic acid

- A naturally occurring bile acid that binds toxic bile acids and allows for their elimination
- Prior studies have shown benefits in reducing meconium passage, preventing fetal arrhythmias and transporting bile acids away from the fetus\(^9,10\)
- A recent meta-analysis showed a reduction in spontaneous preterm birth with the use of Ursodiol. This study was not powered to detect a difference in stillbirth risk\(^11\)
- SMFM recommends Ursodiol as a first line treatment for cholestasis even if the fetal benefit on stillbirth is not clear\(^4\)
- Dosing is 10-21 mg/kg/day in divided doses; may increase dose to help control bile acid levels
- May also improve itching

FOLLOW-UP

- Laboratory evaluation postpartum with CMP and total bile acid levels
- Some patients will have an underlying liver condition such as autoimmune hepatitis. This is more common in early or severe cases
- There is also a high recurrence rate of 70-90% in subsequent pregnancies

MONITORING:

- Although all stillbirths in cholestasis pregnancies are not able to be prevented by fetal monitoring, it is still recommended
- SMFM also recommends following bile acid levels in pregnancy
  - Exact frequency not determined
  - Should be followed closely in later pregnancy to determine optimal delivery timing
- Betamethasone should also be given for planned delivery prior to 37 weeks gestation

Learn more at icpcare.org

501(C)(3) nonprofit
WHAT IS INTRAHEPATIC CHOLESTASIS OF PREGNANCY?
A pregnancy disorder in which bile acid transport in the liver is affected by the hormones of pregnancy

- Leads to increased maternal bile acids which can then affect the fetus
- Main symptom is itching
  - Worse at night
  - Classically involves the palms and soles but usually generalized
- Most cases occur in the second and third trimesters but there are cases that have occurred as early as 5 weeks.¹
- Has a genetic predisposition. Some patients have underlying liver conditions such as autoimmune hepatitis or Hepatitis C

WHAT ARE THE RISKS OF STILLBIRTH?
- Rates linked to bile acid levels based on recent meta-analysis of 5000 cholestasis pregnancies
- Highest risk of 3.44% with bile acids above 100 µmol/L
- Risk for bile acids less than 40 µmol/L was 0.13% and with bile acids 40-99 µmol/L was 0.28%²
- These rates were determined by a meta-analysis where many women were treated with ursodeoxycholic acid and majority delivered by 38 weeks. It is unknown if the active management of these pregnancies might have mitigated some of the stillbirth risk
- Stillbirth is an acute event, possibly a fetal cardiac arrhythmia
- Stillbirth is not prevented with fetal monitoring

WHAT ARE THE RATES OF STILLBIRTH?

- Meconium passage
- Preterm labor
- Increased rates of gestational diabetes and preeclampsia
- Respiratory distress in neonate (even when corrected for gestational age at delivery)³
- Stillbirth

DIAGNOSIS OF CHOLESTASIS

- Laboratory evaluation: CMP and total bile acid test
- Serum bile acid diagnostic level of 10 µmol/L agreed upon by research⁴,⁵,⁶,⁷
- Reference ranges for many bile acid tests are non-pregnancy reference ranges and SMFM notes that the level of 10 µmol/L should be used
- Bile acid test should be non-fasting. Fasting artificially lowers levels
- Fractionated bile acid tests have a lower reference range for diagnosis⁴

TREATMENT

Delivery timing

- Current guidelines in the US per ACOG and SMFM are based upon bile acid levels⁶,⁸

These are:

• For bile acids >100 µmol/L: delivery at 36 0/7 weeks. Consideration for delivery 34-36 weeks with unremitting itch, history of stillbirth due to cholestasis or worsening liver functions
• For bile acids 40-99 µmol/L: delivery 36 0/7-39 0/7 weeks, with delivery recommended in the early portion of the window
• For bile acids below 40 µmol/L: delivery 36 0/7-39 0/7 weeks

• Delivery should be:
  - Based upon highest ever bile acid
  - Individualized per patient
  - In the early portion of the 36 0/7-39 0/7 week window with the exception of mild cases (bile acids below 40 µmol/L)

• Please see our website for an in depth discussion of the evidence behind these recommendations